Can artificial intelligence identify effective COVID-19 therapies?

Schultz, Michael B; Vera, Daniel; Sinclair, David A

Schultz, Michael B; Vera, Daniel; Sinclair, David A.

Schultz MB; Paul F. Glenn Center for Biology of Aging Research, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Vera D; Paul F. Glenn Center for Biology of Aging Research, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Sinclair DA; Paul F. Glenn Center for Biology of Aging Research, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.

EMBO Mol Med ; 12(8): e12817, 2020 08 07.

Article in English | MEDLINE | ID: covidwho-610773

ABSTRACT

ABSTRACT

In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19. Using liver organoids infected with SARS-CoV-2, they confirm dual antiviral and anti-inflammatory activities and show that its administration in four COVID-19 patients is correlated with disease improvement, paving the way for more rigorous placebo-controlled trials.

Subject(s)

Betacoronavirus; Coronavirus Infections; Pandemics; Pneumonia, Viral; Artificial Intelligence; Azetidines; COVID-19; Humans; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Betacoronavirus Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: EMBO Mol Med Journal subject: Molecular Biology Year: 2020 Document Type: Article Affiliation country: Emmm.202012817

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google